Is it reasonable to extrapolate data from Glioblastoma and discuss Tumor Treating Fields in patients with Grade 4, IDH Mutant, astrocytomas?
Answer from: Radiation Oncologist at Community Practice
There is limited data on using TTF in IDH-mutated tumors. There were a total of 25 patients who had known IDH mutations with 19 receiving TTF vs 6 TMZ alone on EF 14 trial. This is too small to generate any subgroup analysis. There are case reports of patients with IDH mutations receiving TTF, one w...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
While more than 90% of Grade 4 gliomas are IDH wildtype tumors (GBMs), this question does come up occasionally. Since I have no personal experience with TTF, I asked my collaborator Chirag Patel, MD, a neuro-oncologist at MDACC who regularly uses TTF in his patients, to provide his opinion. So pleas...